Kiniksa Pharmaceuticals International, plc
KNSA
Clasificación en acciones
#2869
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Precio por acción
$83.13
Última sincronización: 2026-10-20
Capitalización bursátil
$6.49B
Cambio (1 día)
4.59%
Cambio (1 año)
113.97%
País
GB
Comercio Kiniksa Pharmaceuticals International, plc (KNSA)
Categoría
Healthcare
Ingresos de Kiniksa Pharmaceuticals International, plc (KNSA)
Ingresos en Jun 2026 TTM: $840.85M
Según los últimos informes financieros de Kiniksa Pharmaceuticals International, plc, los ingresos actuales de la empresa (TTM) son $840.85M. En 2023, la empresa obtuvo unos ingresos de $270.26M un aumento con respecto a los ingresos del año 2022, que fueron de $220.18M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Kiniksa Pharmaceuticals International, plc desde 2016 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $840.85M | 98.67% |
| 2024 | $423.24M | 56.60% |
| 2023 | $270.26M | 22.74% |
| 2022 | $220.18M | 471.24% |
| 2021 | $38.54M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $2.54B | 201.60% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $830.81M | -1.19% |
US
|
